Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection

Journal of Virology

Volumn 74, Issue 14, 2000, Pages 6262-6268

  Frost, Simon D W ^a,c   Nijhuis, Monique ^b   Schuurman, Rob ^b   Boucher, Charles A B ^b   Leigh Brown, Andrew J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Inst of Cell Anim and Pop Biol   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ISOLEUCINE; LAMIVUDINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; EVOLUTION; GENETIC DRIFT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, MICROBIAL; GENE FREQUENCY; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; POINT MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SELECTION (GENETICS); STOCHASTIC PROCESSES; VIRAL LOAD;

EID: 0033946764     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.14.6262-6268.2000     Document Type: Article

References (31)

1. Back, N. K. T., M. Nijhuis, W. Keulen, C. A. B. Boucher, B. B. O. Essink, A. B. P. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
2. Bonhoeffer, S., J. M. Coffin, and M. A. Nowak. 1997. Human immunodeficiency virus drug therapy and virus load. J. Virol. 71:3275-3278.
3. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
4. Chun, T. W., L. Carruth, D. Finzi, X. F. Shen, J. A. Di Giuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y. H. Kuo, R. Brookmeyer, M. A. Zeiger, P. Barditch Crovo, and R. F. Siliciano. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
5. Coffin, J. M. 1995. HIV population dynamics in vivo - implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
6. Crow, J. F., and M. Kimura. 1970. An introduction to population genetics theory. Harper & Row, New York, N.Y.
7. Eastman, P. S., J. Mittler, R. Kelso, C. Gee, E. Boyer, J. Kolberg, M. Urdea, J. M. Leonard, D. W. Norbeck, H. Mo, and M. Markowitz. 1998. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (norvir) monotherapy. J. Virol. 72:5154-5164.
8. Gerrish, P. J., and R. E. Lenski. 1998. The fate of competing beneficial mutations in an asexual population. Genetica 103:127-144.
9. Haldane, J. B. S. 1927. A mathematical theory of natural and artilicial selection. Proc. Camb. Phil. Soc. 28:838-844.
10. Havlir, D. V., S. Eastman, A. Gamst, and D. D. Richman. 1996. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70:7894-7899.
11. Hill, W. G., and A. Robertson. 1966. The effect of linkage on limits to artificial selection. Genet. Res. 8:269-294.
12. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 cells. Nature 373:123-126.
13. Ji, J., and L. A. Loeb. 1994. Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV-1 env gene. Virology 199:323-330.
14. Kaye, S., C. Loveday, and R. S. Tedder. 1992. A microtitre format point mutation assay - application to the detection of drug resistance in human immunodeficiency virus type 1 infected patients treated with zidovudine. J. Med. Virol. 37:241-246.
15. Kemp, S. D., C. Shi, S. Bloor, P. R. Harrigan, J. W. Mellors, and B. A. Larder. 1998. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J. Virol. 72:5093-5098.
16. Kendall, D. G. 1948. On some modes of population growth leading to R. A. Fisher's logarithmic series distribution. Biometrika 35:6-15.
17. Keulen, W., N. K. T. Back, A. van Wijk, C. A. B. Boucher, and B. Berkhout. 1997. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 71:3346-3350.
18. Kotz, S., and N. L. Johnson (ed.). 1989. Encyclopedia of statistical science. Wiley, New York, N.Y.
19. Leigh Brown, A. J. 1997. Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc. Natl. Acad. Sci. USA 94:1862-1865.
20. Leigh Brown, A. J., and D. D. Richman. 1997. HIV-1: gambling on the evolution of drug resistance? Nat. Med. 3:268-271.
21. Liang, K. Y., and S. L. Zeger. 1986. Longitudinal data analysis using generalized linear models. Biometrika 73:13-22.
22. Nijhuis, M., K. Schuurman, D. de Jong, R. van Leeuwen, J. Lange, S. Danner, W. Keulen, T. de Groot, and C. A. B. Boucher. 1997. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J. Infect. Dis. 176:398-405.
23. Nijhuis, M., C. A. B. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert. 1998. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease inhibitor therapy. Proc. Natl. Acad. Sci. USA 95:14441-14446.
24. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 271:1582-1586.
25. Rouzine, I. M., and J. M. Coffin. 1999. Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc. Natl. Acad. Sci. USA 96:10758-10763.
26. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
27. Syvanen, A. C., K. Aalto-Setala, L. Harju, K. Kontula, and H. Soderlund. 1990. A primer-guided nucleotide incorporation assay in the gcnotyping of apoliprotein-E. Genomics 8:684-692.
28. Van Leeuwen, R., C. Kallama, V. Kitchen, C. A. B. Boucher, R. Tubiana, M. McBride, D. Ingrand, J. Weber, A. Hill, H. McDade, and S. A. Danner. 1995. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection - a phase I/II study. J. Infect. Dis. 171:1166-1171.
29. Wainberg, M. A., M. Hsu, Z. X. Gu, G. Borkow, and M. A. Parniak. 1996. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC resistant HIV-1 reverse transcriptase. AIDS 10(Suppl. 5):S3-S10.
30. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency type 1 infection. Nature 373:117-122.
31. Wright, S. 1969. Evolution and the genetics of populations: a treatise, vol. 2. The theory of gene frequencies. University of Chicago Press, Chicago, Ill.